logo
logo

Actio Biosciences Appoints Cayce Denton As Chief Financial Officer

Jan 08, 2025•6 months ago

Position

Chief Financial Officer

Company

Actio Biosciences

Cayce Denton
San DiegoTherapeuticsBiotechnologyHealth Care

Description

Actio Biosciences has appointed Cayce Denton as chief financial officer. Ms. Denton brings over two decades of experience in finance, strategy, and business development within the biotech and pharmaceutical industries, most recently serving as general partner at Dandelion Capital Management.

Company Information

Company

Actio Biosciences

Location

San Diego, California, United States

About

Actio Biosciences is leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs targeting the underlying cause of disease where biological risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Actio is advancing two lead rare disease programs – ABS-0871 and ABS-1230 – with first-in-class potential for the treatment of Charcot Marie Tooth disease, Type 2C (CMT2C) and a rare genetic epilepsy, respectively. Founded in October 2021, the San Diego-based company is led by experts in genetics and drug development and backed by top healthcare investors.

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Related People

Dimitrios hidden

hidden

David B. hidden

hidden

Cayce hidden

hidden